Trial Profile
A Retrospective study to evaluate the safety and efficacy of Switching Etanercept (Enbrel) to Biosimilar (Benepali) in Wales, United Kingdom
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2018
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Discoid lupus erythematosus; Graft-versus-host disease; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting